 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Lorus Therapeutics Announces Dramatic Anti-Tumor Results For GTI 2040 - GTI 2040 demonstrates complete regressions in in vivo combination studies - ******* make sure you check out the biography section of the company website ********* TORONTO--(BUSINESS WIRE)--Nov. 22, 1999-- Lorus Therapeutics Inc.(TSE: LOR.) (ME: LOR.) (OTC Bulletin Board: LORFF) ("Lorus") today announced dramatic results of recent anti-tumor studies with GTI 2040, including complete tumor regressions, when used in combination with certain chemotherapeutic agents. The results were based on in vivo studies performed using recognized human kidney cancer, colon cancer and melanoma models. The studies were performed at the Company's research facilities at the Sunnybrook Health Science Centre in Toronto, Canada and have been confirmed through repeat experiments. Lorus reported that when SCID mice bearing a human kidney cancer line were treated with a combination of GTI 2040 and two commonly used chemotherapy drugs (5-fluorouracil or vinblastine), complete tumor regression was observed in all the mice treated. The Company also reported that similar tumor regressions were observed in studies combining GTI 2040 and another commonly used chemotherapy drug, mitomycin C in in vivo mouse models of human melanoma and human colon cancer. GTI 2040 also significantly enhanced the anti-tumor effects of other well-known anti-cancer drugs such as gemcitabine, estramustine and paclitaxel in a standard human colon carcinoma mouse model. "We already know that GTI 2040 performs extremely well when used alone, however, these results demonstrate that GTI 2040 has even more striking anti-cancer properties when used in combination with established chemotherapeutic agents", said Philippe G. Lacaille, CEO at Lorus. "Complete regression of tumors is rare but it remains the ultimate goal of any new anti-cancer drug. These results could be very significant to patients with these diseases because of the dramatic effects GTI 2040 has shown in combination with widely used chemotherapeutic drugs. We are extremely encouraged by these results and we look forward to starting our clinical trials as soon as possible." Lorus announced on November 16, 1999 that it had filed an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for the Company's anti-cancer drug, GTI 2040. In its press release, the Company reported that GTI 2040 had demonstrated exceptionally strong anti-tumor properties when tested with a wide range of human tumors in animal models, including tumors derived from lung, breast, colon, liver, ovary, kidney and pancreas. Lorus is a biopharmaceutical company focused on the development of cancer therapies. Lorus' goal is to capitalize on its pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late stage clinical development and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange and the Montreal Stock Exchange under the symbol LOR and on the OTC-BB exchange under the symbol LORFF. Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual reports and 20-F filings. Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: lorusthera.com Contact: Lorus Therapeutics Inc. Philippe G. Lacaille, 905/ 305-1100, ext. 234 905/ 305-1584 (FAX) info@lorusthera.com | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2024 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |